We built LOAM because we believed the microbiome was the overlooked piece of our health: the root system underneath everything from our digestion to our immunity, metabolism, and mood. All of it starts in the gut.
We also believed we could actually do something about it. So we didn't just set out to build a best-in-class formula—we always intended to prove it with a clinical trial.
The GRASP study is our first human trial measuring exactly what LOAM does inside the gut. 30 days, double-blind, with real microbiome sequencing data analyzed by independent researchers. Proof, not promises.
The results are in—and what we learned is that with consistent use of LOAM, the microbiome significantly changes. Let’s take a closer look at exactly how.
A Quick Note on the Science
GRASP stands for Gut Resilience And Symptom improvement with Prebiotics. The GRASP trial used stool microbiome sequencing to analyze gut bacteria before and after 30 days with two different dosages of LOAM supplementation, compared against a placebo group. This kind of analysis gives us a detailed picture of which bacteria are present, how abundant they are, and how the overall community changes over time. The placebo-controlled, double-blind approach is the gold standard trial structure for understanding what a prebiotic is actually doing inside the gut—and this kind of clinical rigor has always been our north star.
Clinical Finding: In 30 Days on LOAM, Gut Communities Shift… Measurably†
LOAM users developed significantly distinct gut microbiome compositions compared to placebo after 30 days, confirmed by two independent statistical methods. In other words, your gut on LOAM looks different from your gut without it, and the difference is statistically meaningful.
This matters because community-level microbiome shifts are notoriously hard to detect in short-term studies. Inter-individual variation—aka the natural differences between people's microbiomes—typically drowns out the signal. Detecting a group-level difference in just 30 days is a meaningful result.
†GRASP Trial, n=47, double-blind placebo-controlled, 30 days
Clinical Finding: The Bacteria That Matter Most Show Up†
The single most enriched bacterium in LOAM users vs. placebo was Roseburia: one of the most important butyrate-producing genera in the human gut. Roseburia ferments prebiotic fiber and produces butyrate, a short-chain fatty acid that fuels the cells lining your gut, helps maintain the gut barrier, suppresses inflammation, and supports immune regulation. More Roseburia means a better-fed, better-protected gut lining.
Alongside Roseburia, LOAM users also showed enrichment of Prevotella and Parabacteroides —both associated with fiber fermentation and additional short-chain fatty acid production.
†GRASP Trial, n=47, double-blind placebo-controlled, 30 days
Clinical Finding: Microbial Richness Holds Steady†
LOAM users maintained their diversity of gut bacterial species over the 30-day period. Placebo users showed a modest decline. This might sound like a small finding, but it isn't. Microbial diversity is one of the strongest predictors of a resilient, well-functioning microbiome—associated with better metabolic health, stronger immune function, and resistance to pathogen colonization. In a world where modern diet, stress, and antibiotic exposure are constantly eroding our inner biodiversity, holding the line is a win worth noting.
†GRASP Trial, n=47, double-blind placebo-controlled, 30 days
Clinical Finding: LOAM enriched the bacteria linked to healthy metabolism†
LOAM users showed enrichment of propionate-producing bacteria—a group linked to blood sugar regulation, healthy satiety signaling, and metabolic health—alongside a dose-dependent shift in the Firmicutes:Bacteroidetes ratio, a widely studied marker of metabolic balance. The higher the dose of LOAM, the more pronounced the shift.
†GRASP Trial, n=47, double-blind placebo-controlled, 30 days
Clinical Finding: LOAM increased immunity-linked bacteria†
LOAM users showed enrichment of bacteria associated with healthy immune modulation, alongside a trend toward reduced activity in hydrogen sulfide production—a metabolite linked to gut inflammation and mucosal damage. Taken together, these shifts suggest LOAM is moving the microbial community in a direction that supports, rather than burdens, your immune defenses.
†GRASP Trial, n=47, double-blind placebo-controlled, 30 days
The Bottom Line
LOAM was built to feed the teeming ecosystem inside of you—with six distinct prebiotic fibers that work together to cultivate a broader, more resilient community. The GRASP trial showed us exactly how this diverse approach manifests in the gut. In 30 days, LOAM users had measurably different gut communities than placebo users, with measurably enriched bacteria to support:
-
Gut barrier health
-
Digestive comfort
-
Immune function
-
Healthy metabolism
-
Appetite signaling
Put simply: LOAM feeds the right bacteria in the gut… and nourishes a blooming microbiome in just 30 days.
You deserve to trust your gut—and that’s why creating a clinically-backed product has always been our floor, not our ceiling. In other words, when it comes to researching the impact of your LOAM, we’re just getting started.
You're 30 days away from a flourishing microbiome. Shop our clinically-backed Prebiotic Fiber Formula.
